NYSE:BHVN

Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

$148.01

0.00 (0.00%)

(As of 08/17/2022 12:00 AM ET)

Add

Compare

Today's Range: $147.97
▼
$148.16
50-Day Range: $143.71
▼
$148.01
52-Week Range: $79.01
▼
$151.51

Volume: 219,844 shs
Average Volume: 1.08 million shs
Market Capitalization: $10.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $157.17

Biohaven Pharmaceutical MarketRank™ Forecast

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 6.2% Upside
$157.17 Price Target
Short Interest: Healthy
8.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.04
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($11.16) to ($7.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars

Medical Sector

1091st out of 1,122 stocks

Pharmaceutical Preparations Industry

539th out of 551 stocks

1.1

Analyst's Opinion

Consensus Rating
Biohaven Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $157.17, Biohaven Pharmaceutical has a forecasted upside of 6.2% from its current price of $147.99.
Amount of Analyst Coverage
Biohaven Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
8.24% of the float of Biohaven Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Biohaven Pharmaceutical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biohaven Pharmaceutical has recently decreased by 1.54%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Biohaven Pharmaceutical does not currently pay a dividend.
Dividend Growth
Biohaven Pharmaceutical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BHVN.

1.1

News and Social Media Coverage

News Sentiment
Biohaven Pharmaceutical has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Biohaven Pharmaceutical this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Biohaven Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biohaven Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.40% of the stock of Biohaven Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.03% of the stock of Biohaven Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($11.16) to ($7.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biohaven Pharmaceutical is -9.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biohaven Pharmaceutical is -9.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Biohaven Pharmaceutical (NYSE:BHVN) Stock

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Analyst Ratings Changes

A number of research analysts recently commented on BHVN shares. Piper Sandler decreased their price target on shares of Biohaven Pharmaceutical from $156.00 to $149.00 and set a "na" rating on the stock in a research note on Tuesday, May 24th. Wedbush lowered shares of Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 target price on the stock. in a research report on Monday, August 8th. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a "buy" rating to a "neutral" rating in a report on Wednesday, May 11th. SVB Leerink downgraded shares of Biohaven Pharmaceutical from an "outperform" rating to a "market perform" rating and set a $150.00 price target for the company. in a report on Wednesday, May 11th. Finally, Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating in a report on Wednesday, May 11th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $157.17.

Biohaven Pharmaceutical Stock Performance

Shares of BHVN Stock opened at $148.01 on Wednesday. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of -9.99 and a beta of 1.03. The company's 50-day moving average is $145.67 and its 200 day moving average is $131.40. Biohaven Pharmaceutical has a one year low of $79.01 and a one year high of $151.51.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

August 17, 2022 | seekingalpha.com

Biohaven: Non-Standard Merger Consideration Makes This A Buy

August 10, 2022 | msn.com

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal

August 10, 2022 | americanbankingnews.com

Biohaven Pharmaceutical (NYSE:BHVN) Stock Rating Lowered by Wedbush

August 9, 2022 | finance.yahoo.com

Get ready for more merger mania in the pharma sector for the rest of the year

August 8, 2022 | finance.yahoo.com

Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

August 5, 2022 | finance.yahoo.com

Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments

August 3, 2022 | finance.yahoo.com

ClearBridge Investments Trimmed its Position in Biohaven Pharmaceutical (BHVN)

August 3, 2022 | apnews.com

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates COWN, SWIR, BHVN, GLTA

July 28, 2022 | nasdaq.com

Notable ETF Outflow Detected - IWM, BHVN, SWAV, HALO

July 28, 2022 | finance.yahoo.com

American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other

July 26, 2022 | apnews.com

The M&A Class Action Firm Continues Investigating the Merger

July 19, 2022 | nasdaq.com

Noteworthy Tuesday Option Activity: BHVN, F, SI

July 16, 2022 | nasdaq.com

IWM, BHVN, SWAV, HALO: Large Outflows Detected at ETF

July 13, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, GRRB, SIMO, MN

July 7, 2022 | finance.yahoo.com

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)

July 7, 2022 | morningstar.com

Biohaven Pharmaceutical Holding Co Ltd - Stock News

July 7, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, PCSB, NLSN

June 29, 2022 | nasdaq.com

Pfizer Stock: Plenty Left in the Vial Despite COVID-19 Waning

June 28, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, USWS, HR, SREV

June 22, 2022 | finance.yahoo.com

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

June 9, 2022 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?

June 9, 2022 | finance.yahoo.com

Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society

June 6, 2022 | apnews.com

SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates HMTV, BHVN, MANT, SWCH

June 1, 2022 | markets.businessinsider.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, MANT, SWCH

May 24, 2022 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Is Breakeven Near?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings: 11/08/2021
Today: 8/17/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:BHVN
Previous Symbol: NASDAQ:BHVN
CUSIP: N/A
CIK: 1689813
Web: www.biohavenpharma.com
Phone: (203) 404-0410
Fax: N/A
Employees: 928
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $157.17
High Stock Price Forecast: $177.00
Low Stock Price Forecast: $146.00
Forecasted Upside/Downside: +6.2%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-846,590,000.00
Net Margins: -108.04%
Pretax Margin: -105.78%
Return on Equity: N/A
Return on Assets: -74.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.75
Quick Ratio: 1.59

Sales & Book Value

Annual Sales: $462.51 million
Price / Sales: 22.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($11.27) per share
Price / Book: -13.13

Miscellaneous

Outstanding Shares: 71,495,000
Free Float: 62,630,000
Market Cap: $10.58 billion
Optionable: Optionable
Beta: 1.03

Key Executives

Dr. Vladimir Coric M.D. (Age 51)
Chairman, CEO & Pres
Comp: $1.81M
Mr. Matthew Buten (Age 61)
Chief Financial Officer
Comp: $766.47k
Ms. Kimberly Gentile (Age 56)
Sr. VP of Clinical Operations
Comp: $1.03M
Dr. Elyse Stock M.D. (Age 63)
Chief Medical Officer
Comp: $1.15M
Mr. William Jones M.B.A. (Age 58)
Chief Commercial Officer of Migraine & Common Diseases
Comp: $1.04M
Mr. Matthew DeLawder
Director of Accounting
Mr. George C. Clark (Age 38)
VP & Chief Accounting Officer
Dr. Charles Conway Ph.D. (Age 60)
Chief Scientific Officer
Ms. Wendy Goss
Exec. Admin. Assistant
Mr. Clifford Bechtold M.S.
Pres & GM of Biohaven Ireland and Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven Pharmaceutical stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings or view top-rated stocks.
What is Biohaven Pharmaceutical's stock price forecast for 2022?: 7 equities research analysts have issued 1-year price targets for Biohaven Pharmaceutical's shares. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they anticipate the company's share price to reach $157.17 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.
How have BHVN shares performed in 2022?: Biohaven Pharmaceutical's stock was trading at $137.81 at the beginning of 2022. Since then, BHVN stock has increased by 7.4% and is now trading at $148.01.
View the best growth stocks for 2022 here.
When is Biohaven Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast.
How were Biohaven Pharmaceutical's earnings last quarter?: Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) released its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The company earned $135.74 million during the quarter, compared to the consensus estimate of $128.40 million. Biohaven Pharmaceutical's quarterly revenue was up 668.5% on a year-over-year basis. During the same period in the previous year, the company earned ($3.27) EPS.
What other stocks do shareholders of Biohaven Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?: (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
What is Biohaven Pharmaceutical's stock symbol?: Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
Who are Biohaven Pharmaceutical's major shareholders?: Biohaven Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.44%), Pentwater Capital Management LP (2.00%), Soros Fund Management LLC (1.76%), TIG Advisors LLC (1.44%), Allspring Global Investments Holdings LLC (1.29%) and JPMorgan Chase & Co. (1.23%). Insiders that own company stock include Declan Doogan, Elyse Stock, Eric Aguiar, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends.
How do I buy shares of Biohaven Pharmaceutical?: Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biohaven Pharmaceutical's stock price today?: One share of BHVN stock can currently be purchased for approximately $148.01.
How much money does Biohaven Pharmaceutical make?: Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.58 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.
How many employees does Biohaven Pharmaceutical have?: The company employs 928 workers across the globe.
How can I contact Biohaven Pharmaceutical?: Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

Biohaven Pharmaceutical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month